Novo Nordisk A/S (NVO) Price Prediction 2026–2050

Novo Nordisk A/S engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa.

Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S (NVO) is a healthcare company with a current price of $47.42 and a market cap of $209.92B, ranking 66th by market capitalization. The stock trades in a sector focused on obesity, diabetes care, and rare diseases, with a broad geographic footprint across Europe, the United States, Asia, and beyond.

The forecast provides year-by-year price expectations. The 2026 average price is $47.42, with a min of $35.29 and a max of $62.85, and an ROI of 0%. By 2030, the average price is expected to be $64.33 with a max of $89.71 and an ROI of 35.7%.

Through 2050, the model projects substantial upside, with the average price reaching $260.87 and a max of $445.09, for an estimated ROI of 450.1%.

Overall, the outlook points to meaningful upside over the long term, with bullish sentiment indicated from the 2027–2035 horizon onward and notable expansion in the later decades, relative to today’s price level.

The multi-year forecast shows a clear path of upside. In 2030, the expected average price is $64.33 with a max of $89.71 and a minimum of $49.36, delivering an ROI of 35.7% and a bullish sentiment. By 2040, the average is projected at $154.74 with a max of $244.54, an ROI of 226.3% and continued bullishness.

The long-horizon forecast extends to 2050, with an average of $260.87, a max of $445.09, an ROI of 450.1%, and a bullish sentiment.

These figures illustrate substantial potential upside over the coming years, supported by rising average prices and rising ROIs, though they are not guarantees and are subject to market risk.